Anand Parikh

Stories

Multi-node PI3K inhibition reaches clinical testing

As of May 2026: Leading combined company's PIKTOR program as COO

Lewis Cantley discovered the PI3K enzyme in 1985. Four decades later, a combination therapy targeting multiple nodes of the pathway he uncovered just demonstrated an 80% response rate in endometrial cancer patients—triple the historical rate with chemotherapy alone. Sensei Biotherapeutics acquired Faeth Therapeutics and raised $200 million to push this approach through pivotal trials.

Updated May 29

Notable Quotes

"PIKTOR is designed to change that tradeoff by inhibiting PI3K-alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability. We saw the signal in our Phase 1b, including a number of complete responses in endometrial cancer patients after multiple prior lines of therapy." — Anand Parikh, February 2026

from Multi-node PI3K inhibition reaches clinical testing · Updated May 29